Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
93 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2017, provides an overview of the Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline landscape. Anorexia is defined as the loss of the desire to eat. Progressive wasting is common in many types of cancer and is one of the most important factors leading to early death in cancer patients. Advanced cancer undergo a wasting syndrome associated with cancer anorexia/cachexia and asthenia. Cancer anorexia or cachexia often is associated with weakness, fatigue, and a poor quality of life. This symptom of anorexia not only affects the patient but also frequently has an impact on family members, as the patient is no longer able to participate fully in eating as a social activity. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Anorexia-Cachexia Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cancer Anorexia-Cachexia Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 1, 1, 9 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 3 molecules, respectively. Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Anorexia-Cachexia Syndrome (Oncology). - The pipeline guide reviews pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Cancer Anorexia-Cachexia Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Anorexia-Cachexia Syndrome (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Cancer Anorexia-Cachexia Syndrome (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Cancer Anorexia-Cachexia Syndrome (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Cancer Anorexia-Cachexia Syndrome - Overview Cancer Anorexia-Cachexia Syndrome - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Cancer Anorexia-Cachexia Syndrome - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Cancer Anorexia-Cachexia Syndrome - Companies Involved in Therapeutics Development Abreos Biosciences Inc Acacia Pharma Ltd Aeterna Zentaris Inc Incyte Corp Lakewood-Amedex Inc Novartis AG Paradigm Biopharmaceuticals Ltd RaQualia Pharma Inc Viking Therapeutics Inc Zeria Pharmaceutical Co Ltd Cancer Anorexia-Cachexia Syndrome - Drug Profiles (formoterol fumarate + megestrol acetate) - Drug Profile Product Description Mechanism Of Action R&D Progress anamorelin hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia - Drug Profile Product Description Mechanism Of Action R&D Progress AV-380 - Drug Profile Product Description Mechanism Of Action R&D Progress AVGN-7 - Drug Profile Product Description Mechanism Of Action R&D Progress C-1889 - Drug Profile Product Description Mechanism Of Action R&D Progress DLN-101 - Drug Profile Product Description Mechanism Of Action R&D Progress ENERGIF-706 - Drug Profile Product Description Mechanism Of Action R&D Progress EXT-400 - Drug Profile Product Description Mechanism Of Action R&D Progress Foxo1-nRNA - Drug Profile Product Description Mechanism Of Action R&D Progress Fusion Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia - Drug Profile Product Description Mechanism Of Action R&D Progress HM-03 - Drug Profile Product Description Mechanism Of Action R&D Progress IP-1510 - Drug Profile Product Description Mechanism Of Action R&D Progress macimorelin acetate - Drug Profile Product Description Mechanism Of Action R&D Progress NEO-1940 - Drug Profile Product Description Mechanism Of Action R&D Progress Recombinant Peptide to Inhibit CIDEA for Cancer Cachexia - Drug Profile Product Description Mechanism Of Action R&D Progress RQ-00433412 - Drug Profile Product Description Mechanism Of Action R&D Progress ruxolitinib phosphate - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptides for Cancer Cachexia - Drug Profile Product Description Mechanism Of Action R&D Progress TCMCB-07 - Drug Profile Product Description Mechanism Of Action R&D Progress VK-5211 - Drug Profile Product Description Mechanism Of Action R&D Progress Z-505 - Drug Profile Product Description Mechanism Of Action R&D Progress Cancer Anorexia-Cachexia Syndrome - Dormant Projects Cancer Anorexia-Cachexia Syndrome - Discontinued Products Cancer Anorexia-Cachexia Syndrome - Product Development Milestones Featured News & Press Releases May 18, 2017: Helsinn Announces Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride) Feb 13, 2017: Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen Jun 01, 2016: Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology Nov 30, 2015: Helsinn Announces European Medicines Agency Acceptance of Marketing Authorization Application for Anamorelin HCL Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology Sep 26, 2014: AVEO Oncology Announces Presentation of AV-380 Preclinical Data at 2nd Cancer Cachexia Conference Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130 Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130 Dec 07, 2011: Helsinn Initiates Extension Study In Late-Stage Anamorelin Clinical Program For Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia Dec 06, 2011: Acacia Pharma Announces Positive Results From Phase IIa Cancer Cachexia Study Nov 28, 2011: FDA Grants IND To Investigator At Baylor College Of Medicine For Phase IIa Trial With AEZS-130 In Cancer Cachexia Aug 24, 2011: Helsinn Therapeutics Initiates Phase III Clinical Program To Evaluate Anamorelin In Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia Apr 26, 2007: Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase II Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June Dec 15, 2005: Sapphire Therapeutics, Inc.'s Oral Ghrelin Mimetic Shows Potential for Treating Cancer Anorexia/Cachexia Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Cancer Anorexia-Cachexia Syndrome, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Cancer Anorexia-Cachexia Syndrome - Pipeline by Abreos Biosciences Inc, H2 2017 Cancer Anorexia-Cachexia Syndrome - Pipeline by Acacia Pharma Ltd, H2 2017 Cancer Anorexia-Cachexia Syndrome - Pipeline by Aeterna Zentaris Inc, H2 2017 Cancer Anorexia-Cachexia Syndrome - Pipeline by Incyte Corp, H2 2017 Cancer Anorexia-Cachexia Syndrome - Pipeline by Lakewood-Amedex Inc, H2 2017 Cancer Anorexia-Cachexia Syndrome - Pipeline by Novartis AG, H2 2017 Cancer Anorexia-Cachexia Syndrome - Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017 Cancer Anorexia-Cachexia Syndrome - Pipeline by RaQualia Pharma Inc, H2 2017 Cancer Anorexia-Cachexia Syndrome - Pipeline by Viking Therapeutics Inc, H2 2017 Cancer Anorexia-Cachexia Syndrome - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2017 Cancer Anorexia-Cachexia Syndrome - Dormant Projects, H2 2017 Cancer Anorexia-Cachexia Syndrome - Dormant Projects, H2 2017 (Contd..1), H2 2017 Cancer Anorexia-Cachexia Syndrome - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
